Skip to main content

A Closer Look at Psoriatic Arthritis Outcome Measures and Disease Control

Sep 01, 2020 7:00 am

A Closer Look at Psoriatic Arthritis Outcome Measures and Disease ControlSlide 2 - Measures of Disease Activity in PsA

Dr. Alexis Ogdie

“...because of the heterogeneous nature of psoriatic arthritis, measuring disease activity is a challenge – there is no single instrument that reflects activity across all disease manifestations.” – Dr. Alexis Ogdie

Audio file
Dr. Philip Mease

“There are generally two approaches when measuring disease activity in psoriatic arthritis – a unidimensional approach and a multidimensional approach.”
– Dr. Philip Mease

Audio file

Slide 3- Disease Domains Affected in Patients With PsASlide 4 - unidimensional and multidimensional composite measures

Dr. Alexis Ogdie

“The DAS28 or CDAI equivalent in PsA is the DAPSA, an arthritis-focused disease activity measure.” – Dr. Alexis Ogdie

Audio file
Dr. Philip Mease

“Data from clinical trials indicate that PASDAS is better at distinguishing treatment effect than DAPSA or DAS28.” – Dr. Philip Mease

Audio file
Dr. Alexis Ogdie

"In my clinical practice, we commonly use both cDAPSA and MDA, since cDAPSA can be calculated from a subset of the MDA elements.”
– Dr. Alexis Ogdie

Audio file
Dr. Philip Mease

“When setting treatment targets for my patients with PsA, I typically evaluate the items that constitute the MDA and VLDA criteria and strive for VLDA if possible.” – Dr. Philip Mease

Audio file

Content developed by AbbVie Inc. This content is intended for US/PR Health Care Professionals. The US Medical Affairs department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content.

AbbVie is solely responsible for all written and oral content within this presentation © 2020 AbbVie Inc. All rights reserved.

AbbVie Inc. ABBV-US-00207-MC, ABBV-US-00208-MC

Approval Date: 09/2020 v1.0

×